www.antena3.ro/economic/companii/americanii-lansea

Eli Lilly has received approval in China for its oral GLP-1 weight loss medication, Orforglipron, marking a significant milestone in the pharmaceutical market. This positions Lilly ahead of Novo Nordisk, which currently offers injectable GLP-1 treatments. The oral medication aims to attract patients who prefer not to use injections. The GLP-1 market in China is projected to grow significantly, with annual sales potentially reaching 30 billion yuan by 2030. Eli Lilly, a major player in the pharmaceutical industry, continues to expand its presence globally, focusing on diabetes and obesity treatments.